Pressemitteilungen zu dem Thema biotech


Unterkategorien

PresseMitteilungen zu dem Schlagwort biotech


NIB finances ESS laboratories and offices in Lund, Sweden

The Nordic Investment Bank (NIB) and the special-purpose vehicle SKR Spallation AB have signed a 23-year loan agreement of EUR 30 million for the construction of offices and laboratories at the site of the European Spallation Source in Lund, Southern Sweden. The project is referred to as the ESS Campus, and includes the construction of laboratories and workshops to support the research conducted at the ESS facility. In addition, office premises with up to 450 work places and a canteen for 200 p ...


08.03.2018

Pharmaceutical Companies Poised to Build Infrastructure to Accommodate Real World Evidence, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing role in drug development during the next three years, but the availability and cost of acquiring data remain key challenges, according to a recently completed study conducted by the .Large pharmaceutical, biotechnology, and contract research organizations plan to increase internal staff dedicated to collection and analysis of real world data by 25% between now and 2020, according to a survey conducted by ...


08.11.2017

Pre-Filled Syringes Europe Attendee List Released

Preliminary attendee list released featuring MHRA, Boehringer Ingelheim, Janssen, Amgen, Merck and Novartis, 3P Innovation, Intertek, Nemera, Terumo, Worrell and Zeon (LONDON, UK) SMi’s Pre-Filled Syringes Europe Conference & Exhibition will take place on 17-18 January at the Copthorne Tara Hotel in London, UK. SMi’s 2017 global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts. Growing year on year, the flagship 10 ...


01.11.2017

APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

APEIRON Biologics AG, a Viennese company focussed on cancer immunotherapy, appointed Peter Llewellyn-Davies as new Chief Financial Officer and Chief Business Officer. The biotech and financial expert Llewellyn-Davies is considered an internationally experienced and recognized transaction specialist. After marketing approval of APEIRON’s immunotherapeutic against neuroblastoma the appointment of this strategically important role should prepare the company for its next phase of growth. APEIRON B ...


13.10.2017

APEIRON Strengthens Management Board with Industry Expert Peter Llewellyn-Davies as New Chief Financial Officer

APEIRON Biologics AG, a private biotech company based in Vienna, Austria, which develops immunotherapies to fight cancer, today announced the appointment of Peter Llewellyn-Davies as Chief Financial Officer and Chief Business Officer. With more than 25 years of experience in initial public offerings (IPOs), mergers & acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, the German-British national is considered one of the most experienc ...


13.10.2017

Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing approval in the United States has declined in recent years, the cardiovascular approval rate trailed other drug approvals as a whole, while the time needed to develop cardiovascular drugs rose, according to a recently completed study conducted by the .Approval success rates for cardiovascular compounds fell from about 5.2% for compounds that began clinical testing during 1995-00, to ab ...


12.09.2017

Investment Plan for Europe: EIB grants financing to Apeiron

Luxembourg, 28th August 2017 - The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the ''European Fund for Strategic Investments'' (EFSI). EFSI is the central pillar of the ''Invest ...


28.08.2017

Investment Plan for Europe: EIB grants financing to Apeiron

Luxembourg, 28th August 2017 - The European Investment Bank (EIB) will provide financing of EUR 25 million to the Austrian biotech company Apeiron Biologics AG (Apeiron). The financing will support the development of new pharmaceutical products to treat cancer, particularly a rare type affecting children. The transaction with Apeiron was made possible by the support of the 'European Fund for Strategic Investments' (EFSI). EFSI is the central pillar of the 'Investment Plan for Euro ...


28.08.2017

Global Nanobiotechnology Market: An Straight Overview of Growth Factors and Future Prospects 2017 – 2025

According to a recently published report by Brisk Insights, the Global Nanobiotechnology Market is expected to grow at the CAGR of 8.2 % during 2017-2025. The global nanobiotechnology market is segmented on the basis of application, technology and geography. The report on global nanobiotechnology market (by application, technology and geography) provides a detailed overview and predictive analysis of the market. Full report available on Nanobiotechnology Market: Global Industry Size, Growth, Sha ...


07.08.2017

Mount Tam Biotechnologies Announces Collaboration to Study Potential in Parkinson''s Disease

NOVATO, CA -- (Marketwired) -- 07/27/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR modulators, is pleased to announce that it has entered into an Agreement with the University of Chile and the Laboratory of Claudio Hetz, Ph.D., to explore the potential of Mount Tam''s novel compounds in Parkinson''s disease. Under this Agreement, Dr. Hetz and his colleagues will use their exten ...


27.07.2017

Kane Biotech Announces Removal of All Debt from its Balance Sheet and Grant of Options

WINNIPEG, MANITOBA -- (Marketwired) -- 07/24/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech") today announced it has paid out all its outstanding debt. This includes its $500,000 convertible note and $400,000 bridge loan.Mark Ahrens-Townsend, President and CEO of Kane Biotech, commented, "The debt proceeds provided value to the Company, however, many prospective investors as well as existing shareholders have voiced their preference for a cl ...


24.07.2017

Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF) have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the .According to Tufts CSDD, 96% of all opioid products prescribed in the U.S. in 2015 lacked abuse-deterrent properties, and only four of the 10 opioid products with abuse-deterrent properties ...


13.07.2017

Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman

CITY OF INDUSTRY, CA -- (Marketwired) -- 07/05/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Dr. Vuong Trieu, has been appointed to serve as Executive Chairman after having served as Chairman of the Board since November of 2016. As Executive Chairman, Dr. Trieu will take on a more active role in the day-to-day o ...


05.07.2017

Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nominees to Nerium''s Board

SAN ANTONIO, TEXAS -- (Marketwired) -- 06/30/17 -- Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, 2017 in Toronto, Ontario, Canada. This year''s Meeting had extraordinary participation from Nerium''s shareholders, with a total of 31,272,131 common shares, or approximately 85.75% of the outstanding common shares of Nerium, hav ...


30.06.2017

Mount Tam Biotechnologies Announces Continuing Oncology Focus

NOVATO, CA -- (Marketwired) -- 06/30/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that recently completed studies support the potential of both TAM-03 and TAM-01 as oncology candidates.Consistent with Mt Tam''s expectations, TAM-01 and TAM-03 produced differentiated activity profiles in an extensive in vitro cancer panel. In particular, increased poten ...


30.06.2017

Lifeline Biotechnologies Updates

RENO, NV -- (Marketwired) -- 06/30/17 -- (OTC PINK: LLBO)The Company recently transferred breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 shares of Cyrcadia, Inc. common stock and a $110,000 cash and $220,000 promissory note. The additional 4,670,000 shares added to Lifeline''s original 8,000,000 shares totals 12,670,000 shares. Lifeline''s ownership is increased to over 45% of Cyrcadia, Inc., making Lifeline Cyrcadia, Inc.''s largest ...


30.06.2017

Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)

CITY OF INDUSTRY, CA -- (Marketwired) -- 06/26/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Erik Emerson will join the company in the newly created role of Chief Commercial Officer, effective immediately.Mr. Emerson most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had found ...


26.06.2017

Marina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy

CITY OF INDUSTRY, CA -- (Marketwired) -- 06/06/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that it has acquired Prestalia®, a treatment of hypertension, from Symplmed Pharmaceuticals Inc. Hypertension remains a significant health issue in the U.S., affecting approximately 34% of adults ages 20 and over, in 2013 to ...


06.06.2017

Kane Biotech Announces Private Placement Offering

WINNIPEG, MANITOBA -- (Marketwired) -- 06/01/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech") today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering") of up to 33,333,333 units ("Units") at a price of $0.12 per Unit for gross proceeds of up to $4,000,000. Each Unit shall be comprised of one common share of the Company (a "Share") and one Share purchase warra ...


01.06.2017

EastGate Biotech''s Recent Acquisition, OMNI Surgery + Anti-Aging Centre, Presents the OMNI School of Medical Esthetics

WEST CALDWELL, NJ and TORONTO, ON -- (Marketwired) -- 05/30/17 -- EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that its recent acquisition, OMNI Surgery and Anti-Aging Centre is introducing the OMNI School of Medical Esthetics.The mission statement of the OMNI School of Medical Esthetics () is to ensure ...


30.05.2017

Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases

CITY OF INDUSTRY, CA -- (Marketwired) -- 05/30/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting two poster presentations at the 22nd Annual Meeting of the RNA Society being held from May 30 to June 3, 2017, in Prague, Czech Republic, at the Prague Congress Center.Dr. Larn Hwang, CSO, is leadin ...


30.05.2017

Plandai Biotechnology Ships 1.2 Million Origine 8 Capsules to Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/22/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that it has successfully shipped an order for 1.2 million Origine 8™ capsules to Coyne Healthcare, a nutraceutical and food supplement company based in South Africa. Origine 8™ is comprised of all eight Phytofare® catechins, which are then entrapped in nutrient-protec ...


22.05.2017

Kane Biotech - Q1 2017 Financial Reports

WINNIPEG, MANITOBA -- (Marketwired) -- 05/17/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" or "Kane Biotech") is pleased to announce its Q1 2017 Financial Results.Highlights:All amounts referenced herein are in Canadian dollars.About Kane Biotech Inc.Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and othe ...


17.05.2017

Kane Biotech - Business and Intellectual Property Update

WINNIPEG, MANITOBA -- (Marketwired) -- 05/11/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" or "Kane Biotech") is pleased to provide an update on its business activities and intellectual property achievements.The Corporation continues to focus the majority of its resources on the development and commercialization of its technologies and products for the companion animal oral care market. Pets have become part of the family and our vision in the companion pet ...


11.05.2017

Accelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals in the United States from 2006 through 2016, and a robust development pipeline suggests that the recent increased pace of biotech approvals will continue for the next decade, according to a newly completed assessment from the .The annual pace of 13 new biotech products approvals by the U.S. Food and Drug Administration during the study period accelerated to more than 20 per year during 2014 ...


09.05.2017

iBio, Inc. Provides Corporate Update at Annual Shareholders Meeting

NEW YORK, NY -- (Marketwired) -- 05/04/17 -- (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Shareholders Meeting held in Bryan, TX.Robert B. Kay, iBio''s Chairman and CEO, stated, "Our achievements over the past year have transformed iBio''s business. In this period, we completed the acquisition, recommissioning and expansion of our Texas plant and equipment for development and c ...


04.05.2017

Global Electronic Health Records (EHR) Software Market to Gain Impetus until 2022, Driven by its Wider Acceptance in Hospitals

Albany, New York, May 04, 2017: The healthcare industry is an entity which constantly changes and improves with the advent of new technology. Currently, the rising demand for streamlining electronic healthcare systems is boosting, which is favorably impacting the market of electronic health records software. The use of EHR software has revolutionized the health industry and has offered a whole new world of operational accuracy to the health concerns. A new study, focusing on this growing market ...


04.05.2017

Plandai Biotechnology Receives 1.2 Million Origine 8 Capsule Order From Coyne Healthcare

LONDON, UNITED KINGDOM -- (Marketwired) -- 05/02/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that it has received an order for 1.2 million Origine 8™ capsules from Coyne Healthcare, a nutraceutical and food supplement company based in South Africa, which we expect to ship this week. Origine 8™ is comprised of all 8 Phytofare® catechins, which are entrapped in ...


02.05.2017

Plandai Biotechnology Names Ezra Jones as Vice President of Sales and Marketing

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/28/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that Ezra Jones has been appointed Vice President of Sales and Marketing, a role he assumes from Callum Cottrell-Duffield, who was recently named Chief Operating Officer of Plandaí.Mr. Jones has been involved in sales of nutraceutical branded ingredients for the past ...


28.04.2017

Marina Biotech to Participate in Joseph Gunnar''s Pioneers 2017 Conference on May 2

CITY OF INDUSTRY, CA -- (Marketwired) -- 04/27/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, announced today that Joseph Ramelli, Chief Executive Officer, will present at Joseph Gunnar''s Pioneers 2017 Conference to be held at the Mandarin Oriental Hotel in New York City on Tuesday, May 2, 2017 at 2:30 pm ET.Investors atte ...


27.04.2017

Eight Dragons Announces the Appointment of Martin Schmieg as Chief Financial Officer

MIAMI, FL -- (Marketwired) -- 04/26/17 -- Eight Dragons Co. (OTC: EDRG) announced today the appointment of Martin Schmieg as Chief Financial Officer. Mr. Schmieg will be responsible for the management and oversight of Eight Dragons'' financial analysis, planning and reporting."We are pleased to welcome Martin to Eight Dragons," said Una Taylor, Chairman and CEO of Eight Dragons. "His experience and expertise in finance at the senior-most levels are critical to ensuring ...


26.04.2017

Cocrystal Pharma Receives Investment Through Private Placement

BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 04/24/17 -- On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the "Company") closed on proceeds of $3,000,000 in a private placement offering (the "Offering") of 12,500,000 shares of the Company''s common stock at a purchase price of $0.24 per share. The purchasers included one of the members of the Company''s board of directors, Chairman Dr. Raymond F. Schinazi. In addition, OPKO Health, Inc. investe ...


24.04.2017

NutriBullets SuperFood Boost Featuring Plandai Biotechnology''s Phytofare Expected to Hit Retailers in May

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/24/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost® featuring Plandaí''s Phytofare® Catechin Complex will be available at retail outlets across the United States as early as May 2017. As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, w ...


24.04.2017

Mount Tam Biotechnologies Announces that the European Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

NOVATO, CA -- (Marketwired) -- 04/21/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to announce that the European Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides com ...


21.04.2017

Plandai Biotechnology New Chief Operating Officer Provides Outlook and Milestones for 2017

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/17/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today released a statement from its new President and Chief Operating Officer, Callum Cottrell-Duffield, providing an overview of the coming twelve months and setting forth the major milestones the Company expects to achieve.Mr. Cottrell-Duffield stated, "Our first agenda item was ...


17.04.2017

EastGate Biotech''s Recent Acquisition OMNI Surgery + Anti-Aging Centre Appoints Dr. Ishaan Sundar as Medical Director

WEST CALDWELL, NJ and TORONTO, ON -- (Marketwired) -- 04/12/17 -- EastGate Biotech Corp. (OTC PINK: ETBI) (), an emerging pharmaceutical company that produces and distributes innovative and healthy nutraceuticals based on natural therapies as well as focusing on new pharmaceutical developments has announced that its recent acquisition, OMNI Surgery and Anti-Aging Centre has appointed a new Medical Director. Dr. Ishaan Sundar has assumed the role of Medical Director effective immediately. Educat ...


12.04.2017

SV Health Investors Closes on New Fund Focused on Creating and Growing Companies That Advance Science and Transform Healthcare

BOSTON, MA -- (Marketwired) -- 04/11/17 -- , the venture capital and growth equity firm formerly known as SV Life Sciences, has closed on its sixth flagship fund. The fund closed at its target of $400 million.SV also manages the Dementia Discovery Fund, plus five other funds that aim to support entrepreneurs and companies that create and deliver breakthrough treatments and healthcare solutions. Together, the seven funds have had capital commitments of more than $2 billion. Over the past 20 year ...


11.04.2017

SV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm''s Longstanding Strategy and Focus

BOSTON, MA -- (Marketwired) -- 04/10/17 -- SV Life Sciences has changed its name to , the healthcare and life sciences venture capital and growth equity firm announced today.The new name is geared to better reflect the firm''s longstanding strategy and multi-sector focus. The firm targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital ...


10.04.2017

Global Uncoated Elisa Kits Sales Market Precise Analysis & Growth Forecast for 2017-2021

Albany, New York, April 10, 2017: During recent times, the demand for uncoated Elisa kits sales has risen due to the great health crisis. Buyers can gain a competitive advantage by studying about this thriving market. The latest study titled ‘Global Uncoated Elisa Kits Sales Market Report 2017’ has been added to the wide repository of Market Research Hub (MRH). The report contains professional evaluation about this growing industry’s reach, growth, and the potential for the forecast 2017-2021. ...


10.04.2017

Marina Biotech Provides Business Update

CITY OF INDUSTRY, CA -- (Marketwired) -- 04/05/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, provided today a corporate update to investors, following the filing of its 10-K for the year ended December 31, 2016 with the SEC.Joseph Ramelli, CEO of Marina Biotech, stated, "Since announcing Marina Biotech''s merger with ...


05.04.2017

Pharmaceutical Biotech Research Company EastGate Biotech Corporation and AC Nova Technologies (ATI Pharma) Announce a Joint Venture to Commercialize Evidence-Based Natural Therapies Focused on Glucose Balance and Cardiovascular Health

WEST CALDWELL, NJ and TORONTO, ON -- (Marketwired) -- 04/04/17 -- EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical and biotech research company that develops, produces and distributes innovative and healthy nutraceuticals, has announced that it has entered into a Joint Venture with AC Nova Technologies Inc. (ATI Pharma). The synergy of talents and products means that these two start-up emerging pharmaceutical companies will now provide expertise starting with formulation deve ...


04.04.2017

Marina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet

CITY OF INDUSTRY, CA -- (Marketwired) -- 04/03/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has signed a definitive agreement with Windlas Healthcare Limited for the manufacture of its IT-102 fixed-dose combination (FDC) bi-layer tablets."This agreement marks the culmination of an in-depth due diligence ...


03.04.2017

Marina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting

CITY OF INDUSTRY, CA -- (Marketwired) -- 03/29/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that three new posters on the use of IT-102 and IT-103 for the treatment of cancer have been selected to be presented at the American Association for Cancer Research Annual Meeting being held on April 1-5, 2017 in Washington, ...


29.03.2017

Apollo Consulting and Trading AG Partner for Biotech JVs and IPO

Zurich (Switzerland), March 29, 2017 – Apollo Consulting & Trading AG advised Swiss-based biotechnology company Biotensidon International AG in all legal matters concerning the build-up of international production capacity for rhamnolipids (natural surfactants). These activities include drafting the company’s IPO strategy and acting as lead consultancy for setting up strategic joint ventures of a German Biotensidon subsidiary with leading key players in their respective industries, among oth ...


29.03.2017

Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest

WINNIPEG, MANITOBA -- (Marketwired) -- 03/27/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") announced that on March 27, 2017, it issued 80,251 common shares of the Corporation ("Common Shares") in payment of $12,439 in interest owing on the Corporation''s $500,000 2 year 10% convertible redeemable unsecured note (the "Note") as at March 18, 2017. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in l ...


27.03.2017

Plandai Biotechnology Names Callum Cottrell-Duffield as New Chief Operating Officer

LONDON, UNITED KINGDOM -- (Marketwired) -- 03/27/17 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® Catechin Complex, today announced that Callum Cottrell-Duffield has been named President and Chief Operating Officer, replacing the Company''s founder, Roger Baylis-Duffield, who will remain Chief Executive Officer. Mr. Cottrell-Duffield has been serving as Vice President of Sales and Marketing ...


27.03.2017

BioStem Technologies, Inc. Announces Completion of 503b Pharmaceutical and Stem Cell Research Laboratory

OAKLAND PARK, FL -- (Marketwired) -- 03/24/17 -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BSEM" or "the company"), an emerging International BioTech company, celebrated the opening of its new laboratory and corporate offices with a ribbon cutting ceremony hosted by the BioStem Technologies executive team. BSEM''s Founder and CEO, Henry Van Vurst, commented, "With the recent regulation changes we amended our original facility design to comply with FDA 503b ...


24.03.2017

Marina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1

CITY OF INDUSTRY, CA -- (Marketwired) -- 03/24/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster(1) on the use of antihypertensive for the treatment of cancer by targeting vascular resistance in the tumor will be presented at the Endocrine Society Annual Meeting to be held on April 1-4, 2017, at Orange ...


24.03.2017

PCI Synthesis Wins Big at 2017 Life Science Leader Magazine CMO Leadership Awards

NEWBURYPORT, MA -- (Marketwired) -- 03/23/17 -- PCI Synthesis, Inc., a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it was recognized as the "Top Overall Performer" in every category the awards are given: Quality, Reliability, Capabilities, Expertise, Compatibility, and Development. The company is the only one this year to earn that designation among its peers ...


23.03.2017

Mount Tam Biotechnologies Announces that the Japan Patent Office Has Allowed a Key Patent for Lead Compound TAM-01

NOVATO, CA -- (Marketwired) -- 03/23/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors is pleased to announce that the Japanese Patent Office has allowed a key patent for TAM-01, a novel mTOR modulator, targeting unmet need in systemic lupus erythematosus (SLE). The patent, owned by the Buck Institute for Research on Aging and licensed exclusively to Mount Tam Biotechnologies, provides comp ...


23.03.2017

EastGate Biotech Acquires a Private Surgery Centre, Omni Surgery + Anti-Aging Centre

WEST CALDWELL, NJ and TORONTO, ON -- (Marketwired) -- 03/14/17 -- EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company that produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that it has entered into a Purchase and Sale Agreement to acquire OMNI Surgery and Anti-Aging Centre. This investment will complement EastGate''s product development initiatives, potential clinical development, bolster revenues positively ...


14.03.2017

Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16

CITY OF INDUSTRY, CA -- (Marketwired) -- 03/13/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that a new poster(1) on the safety and tolerability findings of the Company''s CEQ508, RNAi therapeutic in Familial Adenomatous Polyposis (FAP) will be presented at the Society of Toxicology 56th Annual Meeting to b ...


13.03.2017

Kane Biotech Announces Completion of Share Consolidation

WINNIPEG, MANITOBA -- (Marketwired) -- 03/10/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" or "Kane Biotech") today announced that, further to the approval by the Corporation''s shareholders obtained on December 16, 2016, the Corporation has completed the consolidation of its issued and outstanding common shares on the basis of one post-consolidation common share for every five pre-consolidation common shares (the "Consolidation") resulti ...


10.03.2017

Streamlined Development Process for Certain New Drug Applications Is Not Facilitating Shorter Approval Times, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 03/08/17 -- The 505(b)(2) approval pathway for new drug applications in the United States, aimed at avoiding unnecessary duplication of studies performed on a previously approved drug, has not led to shorter approval times, according to a recently completed analysis conducted by the ."While the 505(b)(2) regulatory pathway has been highly successful in bringing new therapies to market from 2009 through 2015, drug products approved under this pathway had a lon ...


08.03.2017

Bioz Launches Next-Generation of Industry''s First and Only Search Engine for Life Science Experimentation

PALO ALTO, CA -- (Marketwired) -- 03/07/17 -- , developers of the world''s first search engine for life science experimentation, today launched the next-generation of its patent-pending search engine platform. The updated cloud technology includes a new user interface, extensive coverage of scientific articles, a new vendor partner program, and a new level of quality and accuracy of search results, while also offering deep insights on how to best use life science products in experimen ...


07.03.2017

Kane Biotech Announces Exclusive License and Distribution Agreement with Dechra

WINNIPEG, MANITOBA -- (Marketwired) -- 03/06/17 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" or "Kane Biotech") is pleased to announce that it has entered into an exclusive license and distribution agreement (the "License Agreement") with Dechra Veterinary Products LLC ("Dechra"), a wholly-owned subsidiary of Dechra Pharmaceuticals PLC (LSE: DPH). Dechra is an international specialty veterinary pharmaceuticals products company with expertis ...


06.03.2017

Marina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France

CITY OF INDUSTRY, CA -- (Marketwired) -- 03/02/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that new data related to its IT-102 and IT-103 will be presented at the 7th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus in Cannes, France on March 2-5, 20 ...


02.03.2017

Marina Biotech to Participate in the 29th Annual ROTH Conference

CITY OF INDUSTRY, CA -- (Marketwired) -- 03/01/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, has been invited to present at the 29th Annual ROTH Conference to be held at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.Joseph Ramelli, Chief Executive Officer of Marina Biotech, is schedule to present on Wednesday, March 15, 2017 at ...


01.03.2017

InteloMed, Inc. to Exhibit Patient Monitoring System for Assessing Dialysis Tolerance at the National Association of Nephrology Technicians Annual Symposium

PITTSBURGH, PA -- (Marketwired) -- 02/28/17 -- a leader in the development of advanced non-invasive systems for intelligent patient monitoring, will exhibit at the upcoming National Association of Nephrology Technicians (NANT) 34th Annual Symposium. InteloMed will feature the CVInsight® Patient Monitoring & Informatics System for continuous monitoring of cardiovascular stress to assess dialysis treatment tolerance.The NANT mission is to promote the highest quality of care for End Stage Ren ...


28.02.2017

Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer

CITY OF INDUSTRY, CA -- (Marketwired) -- 02/21/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Seymour Fein, M.D., as Chief Medical Officer"I am thrilled to welcome Dr. Fein to the Marina Biotech team," stated Joseph W. Ramelli, CEO of Marina Biotech. "His strong background and experti ...


21.02.2017

Marina Biotech Announces Key Additions to its Executive Management Team

CITY OF INDUSTRY, CA -- (Marketwired) -- 02/14/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced the appointment of Larn Hwang, Ph.D. as Chief Scientific Officer and Mihir Munsif as Chief Operating Officer."We are thrilled to have Larn and Mihir join the Marina Biotech team," stated Joseph W. Ramelli, CEO of Ma ...


14.02.2017

Label-free Array Systems Market to grow substantially with a CAGR of 5.6% during the period 2016- 2024

Albany, New York, February 14, 2017: Market Research Hub (MRH) has recently announced the inclusion of a new study to its market intelligence database, which is entitled as “Label-free Array Systems Market- Global Industry Analysis 2016-2024”. The report analyzes the global market with an in-depth investigation of some of the major regions including North America, Asia-Pacific, Latin America, Europe and Middle East & Africa. Moreover, this report studies the current scenario as well as the ...


14.02.2017

Mount Tam Biotechnologies Announces TAM-03, a Novel Compound with Potential to Treat a Range of Cancer Types

NOVATO, CA -- (Marketwired) -- 02/13/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, announces that it will advance a novel ''rapalog'', TAM-03, for further development efforts with the ultimate goal of moving TAM-03 into the clinic to treat certain advanced cancers for which current therapies are inadequate. TAM-03 delivers a differentiated mTORC1:2 profile, one that ...


13.02.2017

Marina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share

CITY OF INDUSTRY, CA -- (Marketwired) -- 02/10/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has entered into two privately negotiated transactions pursuant to which it will issue an aggregate of approximately 6.15 million shares of its common stock for an effective price per share of $0.29. As a result of su ...


10.02.2017

Mount Tam Biotechnologies, Inc., to present at Bio CEO & Investor Conference

NOVATO, CA -- (Marketwired) -- 02/09/17 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors to treat a range of serious disease states, is pleased to announce that it will be presenting at the Bio CEO & Investor Conference in New York City.The Company''s CEO, Richard Marshak, will present on Tuesday February 14, at 11:30 am EST and will be holding a series of one-on-one meeting thr ...


09.02.2017

Marina Biotech Announces a License Agreement to SMARTICLES

CITY OF INDUSTRY, CA -- (Marketwired) -- 02/07/17 -- Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement regarding the Company''s SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. This represents the first t ...


07.02.2017

Global Joint Venture Partnering Biotech and Diagnostics Industry Analysis 2010-2017

Albany, New York, February 07, 2017: Market Research Hub has recently announced the addition of a new report to it broad database titled as “Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017”. The Global report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type= ...


07.02.2017

PAREXEL Announces Definitive Agreement to Acquire The Medical Affairs Company

Acquisition will strengthen and add scale to current commercialisation and medical affairs services LONDON, February 2, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire The Medical Affairs Company, LLC (“TMAC”), a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries. The acquisitio ...


02.02.2017

PCI Synthesis picks up Life Science CMO Leaderships Awards in all six categories

NEWBURYPORT, MA -- (Marketwired) -- 02/01/17 -- PCI Synthesis, Inc. (), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has won six Life Science Leader CMO Leadership Awards. The company won in every category: Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.This is the fourth consecutive year that PCI Synthesis has been awarded multiple CM ...


01.02.2017

Brown Technical Media Corp. Launches New Microsite Dedicated to Electrical Wholesalers

HOUSTON, TX -- (Marketwired) -- 01/31/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has launched a new state of the art micro website () targeted towards servicing over 3000 electrical wholesale outfits. Brown''s recent acquisition of National Electric Wholesale Providers (NEWP) has established Brown as one of the largest wholesalers of electrical codes and electrician exam prep materials in the United S ...


31.01.2017

Court Schedules Hearing To Consider Approval Of Settlement Of Derivative Action

NEW YORK, NY -- (Marketwired) -- 01/27/17 -- iBio, Inc. (NYSE MKT: IBIO) On January 20, 2017, the Supreme Court for the State of New York, County of New York, scheduled a hearing to consider approval of a settlement of the derivative action captioned Spencer Savage and Yousef Barakat, Derivatively on Behalf of iBio, Inc., Plaintiffs, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant, ...


27.01.2017

Brown Technical Media Corp. Completes Acquisition of One Exam Prep

HOUSTON, TX -- (Marketwired) -- 01/27/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has closed the acquisition of One Exam Prep, LLC (OEP), , a Florida limited liability company, pursuant to the executed binding letter of intent announced on December 15, 2016. OEP is in the business of exam preparation with a focus on construction training and certification.OEP is based in Coconut Creek, Florida and offers eLearni ...


27.01.2017

Cellestia Biotech AG: Cellestia Biotech raises CHF 8M seed financing

BASEL, SWITZERLAND -- (Marketwired) -- 01/26/17 -- Cellestia Biotech AG -Basel, Switzerland - January 26, 2017 - Cellestia Biotech AG, a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway, today announced the final closing of its seed financing rounds securing a total of CHF 8 million in funding.The total seed financing includes proceeds of CHF 0.5 million Seed A and CHF 2.3 million Seed B financing rounds conducted during 2016 and ...


26.01.2017

Brown Technical Media Corp. Closes the Acquisition of National Electric Wholesale Providers with $1.2M in Revenue

HOUSTON, TX -- (Marketwired) -- 01/20/17 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTCQB: PBYA) is pleased to announce today that it has closed the acquisition pursuant to the executed binding letter of intent announced on December 2, 2016 to acquire Premier Purchasing and Alliance LLC, a New York limited liability company also known as National Electrical Wholesale Providers (NEWP). NEWP is in the business of servicing electrical wholesalers throughout the Unit ...


20.01.2017

Brown Technical Media Corp. Announces Uplist to the QB Tier of the OTC Markets

HOUSTON, TX -- (Marketwired) -- 01/18/17 -- Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTCQB: PBYA), an e-commerce company building the first full service training and career advancement brand for the skilled trades, is pleased to announce today that it has been accepted for up listing to the OTCQB effective immediately.To qualify for the listing, Panther has demonstrated that it is current in its reporting requirements to the Securities and Exchange Commission and c ...


18.01.2017

Brown Technical Media Corp. Announces Record Sales for 2016

HOUSTON, TX -- (Marketwired) -- 01/13/17 -- Brown Technical Media Corp., a division of Panther Biotechnology Inc. (OTC PINK: PBYA), is pleased to announce today that it has achieved record sales for the calendar year 2016 for its line of products in e-learning and training, exam preparation, continuing education and compliance materials for career advancement for a wide variety of technical fields. Brown is building the first full service training and career advancement brand for the skilled tr ...


13.01.2017

Poor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development

BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable discussing, clinical trials, they refer a mere fraction of their patients for these studies, reflecting, in part, a failure by sponsors, contract research organizations, and investigative site personnel to engage health care providers as partners in the clinical research process, according to a recently completed analysis conducted by the .The study, based on a survey of 2,000 physicians ...


11.01.2017

Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region

LOS ANGELES, CA -- (Marketwired) -- 01/11/17 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, today announced that the company has completed key steps under its strategic initiative to expand production of its Stellar KLH products.This week, the company established a wholly owned Mexican subsidiary under the name BioEstelar, ...


11.01.2017

Plandai Biotechnology Announces Share Exchange Between Protext Mobility and Plandai''s South Africa Subsidiary

BOCA RATON, FL -- (Marketwired) -- 01/10/17 -- Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that it has completed a share exchange between Plandaí Biotechnology South Africa (PTY) LTD "Plandaí SA," and Protext Mobility, Inc. (OTC PINK: TXTM) "Protext", a Delaware company. Under the terms of the Exchange Agreement, Plandaí became the majority owne ...


10.01.2017

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA -- (Marketwired) -- 01/09/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.Company CE ...


09.01.2017

Brown Technical Media Corp. Moves into $35 Billion Virtual Reality Market via HVAC Training

HOUSTON, TX -- (Marketwired) -- 01/05/17 -- Brown Technical Media Corp., a division of Panther Biotechnology (OTC PINK: PBYA), is pleased to announce today that it has executed an exclusive distribution and publishing agreement with The Training Center of Air Conditioning and Heating, (). This transaction further expands Brown''s strategy to utilize virtual reality in the eLearning segment of its business.Brown is disrupting the technical vocations training and certification industry ...


05.01.2017

Stellar Biotechnologies to Present at Biotech Showcase Conference

LOS ANGELES, CA -- (Marketwired) -- 01/04/17 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual Biotech Showcase conference to be held January 9 - 11, 2017 in San Francisco, California.Monday, January 9, 2017 10:00 am Pacific Time Hilton ...


04.01.2017

Marina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing

CITY OF INDUSTRY, CA -- (Marketwired) -- 01/03/17 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that the European Patent Office intends to grant the company a patent for Bacteria Mediated Gene Silencing (EP 08768475.9, European Patent 2173875).The granted claims relate to the company''s tkRNAi technology bein ...


03.01.2017

Marina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase

CITY OF INDUSTRY, CA -- (Marketwired) -- 12/27/16 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that the company''s Chief Executive Officer, Joseph W. Ramelli, and its Chairman, Dr. Vuong Trieu, will present a corporate update of the recent merger with IthenaPharma and clinical updates of the company'� ...


27.12.2016

Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest

WINNIPEG, MANITOBA -- (Marketwired) -- 12/21/16 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation") announced that on December 21, 2016, it issued 251,385 common shares of the Corporation ("Common Shares") in payment of $12,569 in interest owing on the Corporation''s $500,000 2 year 10% convertible redeemable unsecured note (the "Note") as at December 18, 2016. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shar ...


21.12.2016

Kane Biotech Announces Results of Special Meeting and Proposed Share Consolidation

WINNIPEG, MANITOBA -- (Marketwired) -- 12/16/16 -- Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" or "Kane Biotech") today announced that a special resolution of the shareholders of the Corporation was passed at the special meeting of shareholders of the Corporation held on December 16, 2016 approving the consolidation of the common shares of the Corporation (the "Common Shares") on a five to one basis (the "Consolidation").The Corporation curre ...


16.12.2016

Panther Biotechnology, Inc. Announces Record Date for Biotechnology Milestone Earn-Out Consideration Shares in Response to Recent Positive Feedback from the FDA

HOUSTON, TX -- (Marketwired) -- 12/16/16 -- Panther Biotechnology, Inc. (OTC PINK: PBYA) or Panther, has announced today that it has set a Record Date or Earn-Out Record Date for shareholders of record to participate in the Earn-Out Consideration afforded to the Earn-Out Shareholders pursuant to the Share Exchange Agreement between Panther Biotechnology, Inc. and Brown Technical Media Corp. filed on November 15th, 2016. The record date for Panther shareholders who are eligible to receive the Ea ...


16.12.2016

Brown Technical Media Corp., a Division of Panther Biotechnology Inc., Signs a Binding Letter of Intent to Acquire One Exam Prep

HOUSTON, TX -- (Marketwired) -- 12/15/16 -- Brown Technical Media Corp., () (Brown), a division of Panther Biotechnology, Inc. (OTC PINK: PBYA) (Panther), is pleased to announce today that it has executed a binding letter of intent to acquire One Exam Prep, LLC () (OEP), a Florida limited liability company, which is in the business of exam preparation with a focus on construction training and certification. OEP will be managed as a new division of Panther.Based in Coconut Creek, Florida, OEP of ...


15.12.2016

Philippe P. Calais to Join Marina Biotech''s Board of Directors

CITY OF INDUSTRY, CA -- (Marketwired) -- 12/14/16 -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for cancer and rare diseases, today announced that Dr. Philippe P. Calais was elected to the Marina Biotech board of directors, which he will join effective January 1, 2017. Dr. Calais currently serves as Chief Executive Officer of Isarna Therapeutics."We are delighted to welcome Philippe to the Mari ...


14.12.2016

Annual Diaceutics Report Illuminates State of Diagnostic Ecosystem in the Pharmaceutical Industry

DUNDALK, IRELAND and PARSIPPANY, NJ -- (Marketwired) -- 12/14/16 -- Today, Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enabling pharmaceutical companies to leverage diagnostic testing, released its annual . The report, which will be presented in a webinar today, is an assessment of 23 pharmaceutical and biotechnology companies with commercial therapies whose clinical and financial impact is highly dependent on the availability or efficie ...


14.12.2016

2017 Biotech Predictions Foretell Race Towards Cloud, e-Commerce and Greater Transparency

PALO ALTO, CA -- (Marketwired) -- 12/13/16 -- , developers of the world''s first search engine for life science experimentation, today highlighted six predictions for how the biotechnology industry will make strides in 2017 to advance health and drug discovery.Bioz predicts that 2017 is the year biotech truly will catch up in terms of adopting new trending and emerging technologies in order to accelerate life science research and ultimately save lives. Not only does this include embra ...


13.12.2016

Immune Therapeutics Statement on the Death of Christopher Pearce, Founder and Chief Operating Officer

ORLANDO, FL -- (Marketwired) -- 12/12/16 -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune Therapeutics"), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer, today announced with immense sadness the passing of Christopher Pearce, one of the founders of Immune Therapeutics and its chief operating officer. Mr. Pearce passed away after a 10-year battle with cancer."This is a very sad time for all of us at Immune T ...


12.12.2016

Stellar Biotechnologies Announces Fiscal Year 2016 Corporate Update Conference Call

LOS ANGELES, CA -- (Marketwired) -- 12/12/16 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, will host a conference call and live webcast on Thursday, December 15, 2016 at 1:30 p.m. ET (10:30 a.m. PT) to discuss its fiscal year 2016 results and to provide an update on its business.To access the webcast of the conference call ...


12.12.2016

Stellar Biotechnologies Appoints Pharma and Capital Markets Experts to Board of Directors

LOS ANGELES, CA -- (Marketwired) -- 12/09/16 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), a leading manufacturer of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, today announced the appointment of Charles V. Olson, D.Sc. and Paul Chun to the company''s Board of Directors."Dr. Olson''s and Mr. Chun''s appointment to our Board comes at an exciting time as we p ...


09.12.2016

Plandai Biotechnology, Inc. Announces South African Department of Health Endorses Access to Medicinal Cannabis

LONDON, UNITED KINGDOM -- (Marketwired) -- 12/08/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced the Parliamentary Portfolio Committee on Health in South Africa outlined a clear plan endorsing the need for greater availability of medicinal cannabis to those who suffer from chronic pain. This action may pave the way for parliament to pass the Medical Innovation Bill ...


08.12.2016

Panther Biotechnology Receives Positive Feedback from the FDA

HOUSTON, TX -- (Marketwired) -- 12/07/16 -- (OTC PINK: PBYA) today announced that it has received positive feedback from the submission presented to the U.S. Food and Drug Administration ("FDA") pursuant to a Pre-IND (Investigational New Drug) meeting with the Division of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the FDA. The purpose of the requested meeting was to obtain FDA''s input regarding Panther''s plans for the dev ...


07.12.2016

Brown Publications Inc., a division of Brown Technical Media Corp., Signs an Exclusive Publishing and Distribution Deal with All Purpose Crane Training

HOUSTON, TX -- (Marketwired) -- 12/05/16 -- Brown Publications Inc. (), a division of Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTC PINK: PBYA), is pleased to announce today that it has executed an exclusive publishing and distribution relationship with All Purpose Crane Training of Upland, California. All Purpose Crane Training (AP) (), established in 2008, provides nationwide mobile crane operator and rigging training and assists operators preparing to obtain a n ...


05.12.2016

Brown Technical Media Corp., a division of Panther Biotechnology, Signs a Binding Letter of Intent to Acquire Premier Purchasing and Alliance LLC

HOUSTON, TX -- (Marketwired) -- 12/02/16 -- Brown Technical Media Corp., a division of Panther Biotechnology, Inc. (OTC PINK: PBYA) is pleased to announce today that it has executed a binding letter of intent to acquire Premier Purchasing and Alliance LLC, a New York limited liability company also known as National Electrical Wholesale Providers (NEWP). NEWP is in the business of servicing electrical wholesalers throughout the United States with electrician related study material including the ...


02.12.2016

Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

LOS ANGELES, CA -- (Marketwired) -- 12/01/16 -- Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer''s and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.: Wednesday, December 7, 2016 ...


01.12.2016

Plandai Biotechnology Receives Initial Purchase Order from NutriBullet LLC

LONDON, UNITED KINGDOM -- (Marketwired) -- 11/30/16 -- Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, is pleased to announce that they have received an initial purchase order from Capital Brands LLC, distributor of the world famous, NutriBullet®, who will feature Phytofare® Catechin Complex as an active ingredient in their nutrient extraction powder mix, "Superfood Fat Burning Boos ...


30.11.2016



All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 156


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.

Categories:


[ more PressReleases ][ RSS-Feed ]